AXIN2 and neoplasm: Using the luminex-based system, we found that MSC2504877 elicited an increase in both TNKS and AXIN2 levels in tumours, peaking at 6–10 hours after drug administration and falling 18 hours after MSC2504877 treatment (Fig. 1G,H), a time course which was shifted when compared to the compound concentration time profile in mice (ttmax = 0.5 h, Cmax = 7 μg/mL; Cl = 2.72 L/h/kg, Fig. 1I), and thus in agreement with a turnover PK/PD model for a single dose administration of MSC2504877.